Amarin Corp Plc (AMRN)

[ziploc_1]

Amarin's downturn can be traced to its loss of patent protection in the U.S....Events have shown that Amarin can't depend on Europe....Amarin should return to a focus on the U.S....with patented MND-2119, replacing Vascepa...and a patented Fixed Dose Combo with a statin and MND-2119...if necessary, with a new U.S.-centric management....The JPM conference on January 10 would be a good opportunity for KM to discuss Amarin's plans for these new products....He has previously stated plans for these products would be announced in Q1of 2023...so now is the right time for this announcement.